Global Biotechnology -Yearly Update 2006

The global biotech industry was estimated to be USD73.12 billion in 2006 compared to USD63.3 billion in 2005 up by 15.49%. There is an increase in the global revenues from Canada and Europe regions which is the new cynosure for the global industry.The segments of the industry along with the major global players of the industry are also discussed with their profiles. This report also has details on mergers and acquisitions in the industry that happened in 2006 and to end the report a future outlook for the industry has also been given.

• 1. Industry Overview
  • 1.1 Industry growth
    • 1.1.2 Industry concentric
    • 1.1.3 Industry analysis
    • 1.1.4 R&D expenditure
    • 1.1.5 Number of players
    • 1.1.6 Financial flow
  • 1.2 References
• 2. Major Markets
  • 2.1 Economy
  • 2.2 Global market
  • 2.3 North America
    • 2.3.1 Biotechnology Industry
  • 2.4 Europe
    • 2.4.1 Biotechnology industry
  • 2.5 Asia- Pacific region
    • 2.5.1 Biotechnology Industry
  • 2.6 References
• 3. Major Players
  • 3.1 Introduction
  • 3.2 Novartis
  • 3.3 Amgen
  • 3.4 Genentech
  • 3.5 Genzyme
  • 3.6 Gilead Sciences
  • 3.7 Biogen Idec
  • 3.8 MedImmune Inc
  • 3.9 Invitrogen
  • 3.10 Merck Serono
  • 3.11 Millennium Pharmaceutical Inc
  • 3.12 References
• 4. Mergers and Acquisitions
  • 4.1 Introduction
  • 4.2 Major Disclosed Deals
  • 4.3 Undisclosed Deals
  • 4.4 Some Major Deals
  • 4.5 Trends in the deals
  • 4.6 References
• 5. Outlook
  • 5.1 References
• List Of Figures
  • Figure 1.1: Biotech Industry Revenues, 2002-2006
  • Figure 1.2: Global Revenue Break-up, 2006
  • Figure 1.3: Global Biotech Industry Net loss, 2002-2006
  • Figure 1.4: Global R&D Expenditure, 2002-2006
  • Figure 1.5: Companies in Biotech Industry, 2002-2006
  • Figure 1.6: Biotech Financing, 2002-2006
  • Figure 2.1: Global Real GDP Growth (2005-06)
  • Figure 2.2: Real GDP Growth Rate in the US (2005-06)
  • Figure 2.3: Real GDP Growth Rate in Canada (2005-06)
  • Figure 2.4: Real GDP Growth Rate in European Union (2005-06)
  • Figure 2.5: Real GDP Growth Rate in Japan (2005-06)
  • Figure 2.6: Real GDP Growth Rate in India (2005-06)
  • Figure 2.7: Real GDP Growth Rate in China (2005-06)
  • Figure 2.8: Major regions of Biotech Industry 2002- 2006
  • Figure 2.9: North American Biotech Revenue, 2002-2006
  • Figure 2.10: North American R&D Expenditure, 2002-2006
  • Figure 2.11: Biotech Companies in North America, 2002-2006
  • Figure 2.12: European Biotech Revenue, 2002-2006
  • Figure 2.13: Biotech Companies in Europe, 2002-2006
  • Figure 2.14: R&D Investment in Europe, 2002-2006
  • Figure 2.15: Biotech Revenue in Asia-Pacific, 2002-2006
  • Figure 2.16: Biotech Companies in Asia-Pacific, 2002-2006
  • Figure 2.17: R&D expenditure in Asia-Pacific, 2002-2006
• List Of Tables
  • Table 1.1: Major IPOs during 2006
  • Table 1.2: Major venture financings during 2006
  • Table 1.3: Selected partnering transactions during 2006
  • Table 1.4: Major drugs approved by FDA during 2006
  • Table 1.5: Major biotech drugs in pipeline (2006)
  • Table 1.6: Some important government R&D funding, 2006
  • Table 2.1: Major companies in North America
  • Table 2.3: Major European Companies 2006
  • Table 3.1: Top 10 Biotechnology Companies, 2006
  • Table 3.2: Novartis 2005- 2006
  • Table 3.3: Amgen 2005- 2006
  • Table 3.4: Genentech 2005-2006
  • Table 3.5: Genzyme 2005-2006
  • Table 3.6: Gilead Sciences 2005-2006
  • Table 3.7: Biogen Idec 2005 - 2006
  • Table 3.8: MedImmune 2005 - 2006
  • Table 3.9: Invitrogen 2005-2006
  • Table 3.10: Merck Serono 2005- 2006
  • Table 3.11: Millennium 2005 - 2006
  • Table 4.1: Major deals announced/completed 2006
  • Table 4.2: Undisclosed deals 2006